Proteome Sciences PLC Directorate Changes (6491M)
01 August 2017 - 4:02PM
UK Regulatory
TIDMPRM
RNS Number : 6491M
Proteome Sciences PLC
01 August 2017
1 August 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Directorate changes
Proteome Sciences (AIM:PRM), is pleased to announce the
appointment of Dr Ursula Ney as a Non-executive Director of the
Company, with immediate effect, replacing Professor William Dawson
who is standing down after providing 20 years of valuable service
to the Company.
Dr Ney has over 30 years' experience in the pharmaceuticals
industry, this includes 20 years in leadership roles in the biotech
sector. She has worked with many of the major US pharma companies
and has a range of skills including product development, business
development, partnering and M&A. Dr Ney has worked for both
public and private companies including Celltech, Roche, Sandoz and
as Chief Operating Officer of Antisoma plc. She is currently a
Non-executive Director of Discuva, a drug discovery company focused
on the creation of next generation targeted antimicrobials against
new emerging and drug-resistant bacterial pathogens.
Commenting on the appointment, Chief Executive Officer, Jeremy
Haigh, said "We are delighted to welcome Dr Ney to the Board of
Proteome Sciences. Her extensive experience of the bioscience
environment, gathered over many years in a range of senior
positions within large and small companies, makes her ideally
suited to a role on the Board at this pivotal stage in the
Company's evolution. I look forward to working closely with her
over the coming months. I would also like to take this opportunity
to thank Professor Dawson for his outstanding service as a Director
of the Company since 1997; Bill's scientific insight has been a
cornerstone of our endeavour for many years and we hope to realise
his vision in the months and years to come."
Dr Ney said "I am delighted to be joining the Board of Proteome
Sciences at this exciting and challenging time for the company and
I look forward to working with all the Board and team to realise
the potential of the proteomics platform."
As announced with the interim results on 25 July, and following
the resignation of Geoff Ellis as Finance Director and Company
Secretary, we are pleased to confirm that Stefan Fuhrmann has been
appointed Interim Finance Director. Mr Fuhrmann has strong
financial and management reporting skills and qualified as an
accountant in the UK. Victoria Birse has been appointed Company
Secretary, having joined Proteome Sciences in March 2015.
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive
Officer
Ian Pike, Chief Scientific Tel: +44 (0)20 7043
Officer 2116
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/James Thompson Tel: +44 (0)20 7220
Tony Quirke (Broking) 0500
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Tel: +44 (0)20 3053
Nolan 8671
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This announcement contains inside information for the purpose of
Article 7 of EU Regulation 596/2014.
Additional information on Dr Ursula Mary Ney
The following additional information is provided in accordance
with Schedule 2(g) of the AIM Rules for Companies:
Current and past Directorships for Dr Ursula Mary Ney, aged
65:
Current Previous (last five years)
Discuva Ltd Genkyotex SA
There are no further disclosures required under Schedule 2(g) of
the AIM Rules for Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABLGDRGBXBGRB
(END) Dow Jones Newswires
August 01, 2017 02:02 ET (06:02 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024